프레스티지바이오파마

950210KOSPI자연과학 및 공학 연구개발업

43.3 / 100

Reference Date: 2026-07-24

Financial Score11.5 / 40

News Sentiment17.8 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PER raises overvaluation concerns, ROE is below the industry average. Declined 12.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Prestige BioPharma is a biopharmaceutical company specializing in biosimilars and monoclonal antibody drug development. Its Herceptin biosimilar HD201 received a positive opinion from the European Medicines Agency (EMA) in 2024, while Avastin biosimilar HD204 and Humira biosimilar PBP1502 are in development. The company's pancreatic cancer treatment antibody drug PBP1510 holds patents in 13 countries, and its CTHRC1-targeting antibody drug PBP1710 is also in development.

Number of Employees

67people

Average Salary

53.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

106279.08Industry Average 43.640.0Point

2435.4x industry avg (risky)

PBR

—Industry Average 2.523.5Point

ROE

0.80Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

14.17Industry Average 7.310.5Point

1.9x industry avg (risky)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲1098.9% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -4.9% (improving, 2yr)

Detailed News Sentiment

5 totalPositive 3Neutral 2Negative 0Average Sentiment Score 71

Neutral
[CDMO 특별법]③'덩치·기술 경쟁'…한단계 끌어올리려면?
The news discusses regulatory support for CDMO companies but focuses on broader industry trends rather than directly impacting 프레스티지바이오파마's stock.
Positive
프레스티지바이오파마IDC, CRS 치료 이중항체 비임상 효능 국제학술지...
프레스티지바이오파마IDC의 CRS 치료 후보물질 IDC007의 긍정적 비임상 효능 결과가 국제 학술지 게재로 인해 긍정적인 시장 반응을 기대할 수 있다.
Neutral
한국계 美 바이오 4社, 코스닥 노크
Four American biotech startups founded by Korean scientists aim for KOSDAQ listing via KDR route, avoiding direct legal conflicts.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 5,260Won52-week high 15,72052-week low 5,030

1-month return1.0Point

1m -12.33% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-09
Neutral주식등의대량보유상황보고서(일반)2026-07-09
Neutral최대주주등소유주식변동신고서2026-07-09
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-01
Neutral최대주주등소유주식변동신고서2026-07-01